Organ-specific and tumor-size-dependent responses to sunitinib in clear cell renal cell carcinoma by Norihiko Tsuchiya et al.
Tsuchiya et al. BMC Urology 2014, 14:26
http://www.biomedcentral.com/1471-2490/14/26RESEARCH ARTICLE Open AccessOrgan-specific and tumor-size-dependent
responses to sunitinib in clear cell renal cell
carcinoma
Norihiko Tsuchiya1, Takeshi Yuasa2, Shinya Maita1, Shintaro Narita1, Takamitsu Inoue1, Kazuyuki Numakura1,
Mitsuru Saito1, Shigeru Satoh1, Junji Yonese2 and Tomonori Habuchi1*Abstract
Background: Tyrosine kinase inhibitors (TKIs) have been used as standard therapy for patients with advanced renal
cell carcinoma (RCC). However, information on factors predicting response to treatment with TKIs is lacking. This
study aimed to assess the association between initial tumor size, involved organs, pre-treatment C-reactive protein
(CRP) levels, and reduction in tumor size in patients with clear cell RCC (CCRCC) treated with sunitinib.
Methods: Patients with advanced CCRCC with target lesions with a maximum diameter ≥ 10 mm treated with
sunitinib were evaluated. The tumor diameter representing the best overall response was designated as the
post-treatment tumor diameter.
Results: A total of 179 lesions in 38 patients were analyzed. Organ-specific analysis demonstrated that
pre-treatment diameter of lung metastatic lesions had a moderate inverse association with percent reduction in
post-treatment tumor diameter (R = 0.341). Lung lesions showed significantly greater percent reductions in diameter
than liver and kidney lesions (P = 0.007 and 0.002, respectively). Furthermore, based on a CRP cut-off level of
2.0 mg/dl, mean tumor size reduction was significantly greater in patients with low CRP levels than in patients with
high CRP levels in lesions with diameters < 20 mm (P = 0.002). CRP level had no effect on mean size reduction in
lesions with a diameter ≥ 20 mm.
Conclusions: Patients with CCRCC with smaller lung metastatic lesions and lower CRP levels may achieve greater
percent reductions in tumor size with sunitinib therapy than patients with extra-pulmonary lesions, large lung
lesions, and/or higher CRP levels.
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In the era of cytokine therapy, tumor response to treat-
ment in advanced or metastatic renal cell carcinoma
(RCC) has been reported to vary according to the organs
involved [1,2]. Longer overall survival and a higher re-
sponse rate to therapy with interferon-α or a combin-
ation of interleukin-2 and interferon-α were observed in
patients with only lung metastasis, compared with those
with extra-pulmonary metastasis [1,2]. Complete remis-
sion (CR) after treatment with tyrosine kinase inhibitors* Correspondence: thabuchi@doc.med.akita-u.ac.jp
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reproduction in any medium, provided the or(TKIs), which mainly target vascular endothelial growth
factor receptors, remains a rare event, but most patients
who do achieve CR have either lung metastasis alone, or
only lymph node involvement [3,4]. However, most can-
cer clinical trials evaluate tumor response using the re-
sponse evaluation criteria in solid tumors (RECIST), in
which the longest diameters of target lesions in multiple
organs are summed. Tumor response in individual meta-
static lesions in specific organs has not been delineated.
A reduction in tumor size >10%, calculated as the sum
of the longest diameter of the target lesions, was signifi-
cantly associated with both time to treatment failure and
overall survival, suggesting that size reduction of target
lesions may predict the outcome of treatment with TKIsl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
Table 1 Patients’ characteristics





















No (biopsy) 8 (21.1)
Prior treatments
None 27 (71.1)
Cytokines alone 4 (10.5)
Sorafenib ± cytokines 7 (18.4)
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a smaller initial tumor size predicted a good response to
TKIs, and that the maximum response was achieved in
lung lesions [6]. TKIs have shown significant clinical
benefit in advanced clear cell RCC (CCRCC) in large
randomized trials [7-9]. However, the reported objective
responses vary according to the different types of TKIs,
and a recent phase II trial failed to demonstrate any clin-
ical efficacy of sunitinib in non-CCRCC [10]. Tumor size
reduction may thus be affected by many factors, includ-
ing initial tumor size, involved organs, tumor histology,
tumor aggressiveness, or type of TKI used. In this study,
we evaluated the association between initial tumor size
of individual lesions in specific organs and reduction
in tumor size in patients with CCRCC treated with
sunitinib.
Methods
Patients and tumor measurement
A total of 38 patients with advanced CCRCC, who re-
ceived at least two cycles of sunitinib at Akita University
Hospital and at the Cancer Institute Hospital of the
Japanese Foundation for Cancer Research, were enrolled
in this institutional, review-board-approved, retrospect-
ive study. Pathological diagnosis was made by radical
nephrectomy in 30 patients and by percutaneous biopsy
in eight patients who were not indicated for surgical
treatment, because of a significantly higher total volume
of metastatic lesions compared with the primary lesion.
The initial dose of sunitinib was 50 mg/day, which was
reduced to 37.5 mg/day based on the patient’s physique,
age, and performance status. Sunitinib was initiated on
a 28 days on/14 days off schedule, and a dose reduction
to 25 mg/day or complete cessation was considered
in the event of grade 3 or higher toxicity, according to
the Common Terminology Criteria for Adverse Events
(CTC-AE). All lesions were evaluated using a multi-
detector computed tomography scanner, and lesions
≥ 10 mm in diameter were considered target lesions.
The maximum diameter of each target lesion was mea-
sured before treatment with sunitinib (pre-treatment
tumor diameter) and every 2–3 months thereafter. The
tumor diameter at the point when best overall response
was achieved, based on the RECIST version 1.0, was
adopted as the post-treatment tumor diameter. In this
study, the most common metastatic organs, including
lung, liver, and lymph nodes, as well as the kidney, were
subjected to analysis.
Statistical analysis
The association between pre-treatment tumor diameter
and percent change between pre- and post-treatment
tumor diameters for each lesion was assessed by
Pearson’s correlation coefficient. The Kruskal Wallis testwas used to compare differences in percent change in
tumor diameter between the four different organs. The
Mann–Whitney U test was used to compare differences
between two groups. A receiver-operator curve (ROC)
was constructed to find the pre-treatment tumor diameter
predicting tumor response to sunitinib treatment. A value
of P < 0.05 was considered statistically significant.
Results
Patients and target lesions
The patients included 30 men and eight women with a
median age of 62 years (range 27–81 years). The pa-
tients’ characteristics are listed in Table 1. The best re-
sponse to sunitinib treatment was CR in one patient
(3%), partial response (PR) in 11 (29%), stable disease
(SD) in 23 (61%), and progressive disease (PD) in three
(8%). The objective response rate was 32% and the cli-
nical benefit rate (CR + PR + SD for at least 3 months)
was 92%. A total of 179 lesions ranging from 10 to
106 mm were measured and analyzed in 38 patients.
These lesions were localized as follows: 124 in the lung,
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ney. Of the 15 patients with kidney tumors, seven who
underwent nephrectomy had target lesions in the contra-
lateral kidney, including two patients with multiple lesions.
The remaining eight patients had primary kidney tumors
that were diagnosed by percutaneous needle biopsy.
Associations between pre-treatment tumor diameter and
percent change in target lesion size in different organs
The associations between pre-treatment tumor diameter
and percent change in size of each target lesion in each
of four organs were analyzed separately. Organ-specific
analysis demonstrated that pre-treatment diameter of lung
metastatic lesions had a moderately positive association
with percent change in post-treatment tumor diameter
(R = 0.341, Figure 1). There were fewer target lesions in
the other three organs than in the lung, and there was
no association between liver, lymph node, or kidney lesion
size and percent change in post-treatment tumor diameter
(Figure 1). The percent changes in target lesion size dif-
fered significantly between the four individual organs (P =
0.0007 by the Kruskal Wallis test). The mean (± SD) per-
cent changes in target lesion size in the lung, liver, lymph
nodes, and kidney were −27.1 ± 33.5, 0.5 ± 29.4, −16.7 ±
19.6, and −2.7 ± 21.7, respectively. Target lesions in the
lung showed the greatest change in size, which was signifi-
cantly greater than in the liver and kidney (P = 0.007 and
0.002, respectively). There was no difference in the per-
cent change in target lesion size between the lung and




























R = 0.341, P = 0.0001
R = 0.121, P = 0.572
Figure 1 Association between pre-treatment tumor size and percent
between pre-treatment tumor size and percent change in size was analyze
The pre-treatment size of lung lesions showed a moderately positive assoc
association was observed in the liver, lymph nodes, and kidney.Lesions in each organ were divided into two groups
according to the median pre-treatment diameter, and
percent changes in tumor diameter were compared be-
tween the two groups. Lung lesions with a pre-treatment
diameter less than the median value of 17.3 mm showed
a significant percent reduction in diameter compared
with tumors ≥ 17.3 mm (P = 0.002). There were no dif-
ferences in the percent change in relation to size above
or below the median value in other organs (Figure 2).
Cut-off value for pre-treatment tumor diameter predicting
response to sunitinib in lung metastasis
ROC curves were drawn to determine cut-off values pre-
dicting 30% and 50% reductions in the diameter of lung
metastatic lesions (Figure 3). The cut-off predicting a
30% reduction in diameter was 16.5 mm, with a sensitiv-
ity of 69.6%, specificity of 58.2%, and an area under the
curve (AUC) of 0.662. The cut-off predicting a 50% re-
duction in diameter was also 16.5 mm, with a sensitivity
of 67.0%, specificity of 77.8%, and an AUC of 0.752.
Using this cut-off value, the percent change in lesion size
for lesions < 16.5 mm was −41.7 ± 35.5%, while that for
lesions ≥ 16.5 mm was −16.2 ± 26.9% (P = 0.0005).
Influence of pre-treatment CRP value, cytoreductive
nephrectomy, and treatment line on percent change in
target lesion size in the lung
Metastatic lung lesions were categorized into two groups
based on pre-treatment C-reactive protein (CRP) levels.




























R = -0.021, P = 0.949
R = -0.341, P = 0.153
change in lesion size after sunitinib treatment. Association
d for lesions in the lung (a), liver (b), lymph nodes (c), and kidney (d).















Lung Liver Lymph node Kidney
Median (mm) 17.3 30.0 25.8 63.3
P = 0.002 P = 0.245 P = 0.773 P = 0.668
P = 0.007 
P = 0.114 
P = 0.002 
Total < Median > Median
124 12 24
19
Figure 2 Percent change in target lesion size in different organs. The reduction in lesion size was significantly greater in lung lesions
compared with liver and kidney lesions. Lung lesions with an initial diameter < 17.3 mm (median) showed a significant percent reduction in size
compared with lesions≥ 17.3 mm. No significant differences in relation to initial lesion size were observed in the liver, lymph nodes, and kidney.
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and −38.3 ± 30.5%, respectively, while those in patients
with CRP ≥ 2.0 mg/ml were 28.3 ± 20.6 mm and −9.6 ±
33.9%, respectively. The lesions were further divided into
three subgroups according to pre-treatment diameter <
20 mm, ≥ 20 to < 40 mm, and ≥ 40 mm. Percent changes
were compared between lesions in patients with CRP <















1 - Specificity 
16.5 mm
16.5 mm
Figure 3 Cut-off values of initial lung tumor size for predicting
30% and 50% reductions in diameter after sunitinib treatment.
Based on ROC analysis, the cut-off values of initial lung lesion size
for predicting reductions in diameter of both 30% and 50% were
16.5 mm.CRP) in each subgroup. For lesions < 20 mm, patients with
low CRP had significantly greater reductions in tumor
diameter than patients with high CRP (−43.8 ± 33.4%
vs. −15.3 ± 37.7%, P = 0.0019). In patients with lesions ≥20
to < 40 mm, there was a tendency towards a greater reduc-
tion in patients with low CRP compared with high CRP,
though the difference was not significant (−29.0 ± 17.3%
vs. −12.4 ± 30.2%, P = 0.054), and similarly there was no
significant association between tumor reduction and CRP
level in patients with lesions ≥ 40 mm (−13.3 ± 20.6 vs.
6.8 ± 17.4, P = 0.151) (Figure 4).
Percent changes in size were compared between lung
lesions in patients in each diameter subgroup who did
and did not undergo cytoreductive nephrectomy. There
were no lung lesions ≥ 40 mm in patients who did not
undergo cytoreductive nephrectomy. There was no sig-
nificant difference between mean percent change in lesion
size in patients with and without cytoreductive nephrec-
tomy (−36.1 ± 32.6 vs. −28.2 ± 41.9, P = 0.421 and −20.4 ±
25.1 vs. −32.0 ± 21.9, P = 0.307 in lesions < 20 mm and
≥ 20 mm, respectively).
Similarly, there was no significant difference in percent
change in lesion size between lung lesions in patients
treated as first-line therapy and those treated as second-line
or later therapy in any diameter subgroup (−38.1 ± 37.7
vs. −32.1 ± 33.9, P = 0.280; −23.5 ± 21.6 vs. −17.5 ± 23.3,
P = 0.803; and 3.5 ± 2.6 vs. 1.9 ± 22.9, P > 0.9 in lesions <
20 mm, ≥ 20 to < 40 mm, and ≥ 40 mm, respectively).
Discussion
A previous study on metastatic RCC by Yuasa et al. de-
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P = 0.0019 P = 0.054 P = 0.151
Tumor size (mm)
CRP < 2.0 CRP ≥ 2.0Total
77 35 12
Figure 4 Influence of CRP on percent change in lung lesion size. In patients with lung lesions < 20 mm, the percent reduction in size was
significantly greater in patients with low, compared with high, CRP levels. Meanwhile, CRP level had a marginal effect on size reduction
in lesions ≥ 20 to < 40 mm, and no effect in lesions ≥ 40 mm.
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achieved in patients with lung lesions; and 3) there was
no difference in tumor response between patients treated
with sorafenib and sunitinib [6]. However, these results
raised several specific questions. First, tumor histology
and progression risk may affect the response to TKIs.
TKIs are associated with a good response in patients with
CCRCC, but are less effective against non-CCRCC [10].
Similarly, patients with favorable risk factors have a
greater chance of a good tumor response than those with
poorer risk factors. Second, there is the possibility of bias
in terms of the types of TKI selected; given that sunitinib
showed a higher response rate than sorafenib [7,8], pa-
tients with larger or more rapidly-growing tumors may be
allocated sunitinib rather than sorafenib in clinical prac-
tice. Third, efficacy based on initial tumor size may dif-
fer between different organs; although the previous study
compared mean lesion-size reductions between different
organs, they did not compare the effect of initial tumor
size in individual organs. It is therefore unclear if the asso-
ciation between initial lesion size and tumor response was
observed in each organ, or if the association could be at-
tributed to the fact that most of the small lesions were
lung metastases, which showed a good response to TKIs.
The current study only included CCRCC patients treated
with sunitinib. We found that lung lesions showed the
greatest response to sunitinib, and detected a modest cor-
relation between initial tumor diameter and reduction in
lesion size, while even small lesions in other organs failed
to respond. However, the number of extra-pulmonary tu-
mors assessed was too small to determine statistical sig-
nificance, and further studies with larger numbers of
tumors are needed to obtain conclusive results.Only lesions with an initial diameter < 20 mm achieved
a CR in this study, indicating that a lung-tumor reduc-
tion of > 50% might be limited to smaller lesions. The
cut-off value of 16.5 mm for a > 50% reduction in diam-
eter was calculated using ROC analysis, with a sensitivity
of 67.0% and a specificity of 77.8%. Some physicians may
prefer conservative therapies without TKIs, or a watchful
waiting strategy, in CCRCC patients with only small
lung metastatic lesions [11]. Furthermore, cytokine ther-
apies are still employed in CCRCC patients, especially in
Japan, because of their low toxicity and ability to achieve
long-term stable disease [12]. However, the present re-
sults suggest that smaller lung lesions are associated with
a greater chance of response to TKIs, and it is therefore
important not to miss the opportunity for early initiation
of TKI treatment in patients with PD during watchful
waiting periods or cytokine therapy.
Several studies have investigated the response of pri-
mary kidney lesions to TKIs [13-15]. Kroon et al. re-
ported that smaller primary lesions were more responsive
to treatment, and that tumors of 5–7 cm may benefit from
neoadjuvant treatment followed by nephron-sparing sur-
gery. In contrast, our results showed that the response
of kidney lesions to sunitinib was independent of initial
tumor size, and many smaller lesions exhibited no res-
ponse. A possible explanation for this difference may be
the selection of patients; most of the kidney lesions
were investigated in the neoadjuvant setting in Kroon
et al.’s study, while all the patients with kidney lesions
in the current study had an extensive metastatic tu-
mor burden. The different patient backgrounds may
have led to different responses to TKIs, particularly in
small kidney lesions.
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response to various conditions, such as inflammation, in-
fection, and malignancy [16]. In the cytokine era, elevated
serum CRP level has been suggested as a biomarker for
predicting poor survival in RCC patients [17-19]. Yasuda
et al. recently demonstrated that CRP was a significant
predictive marker for prognosis in metastatic RCC pa-
tients treated with TKIs [20]. In the current study, the size
reduction of lung lesions in patients with high serum CRP
levels was lower than that in patients with low CRP levels,
irrespective of the initial size. This lower response to suni-
tinib in patients with higher serum CRP levels may be at-
tributed to an aggressive disease status, reflected by higher
CRP levels, the acquisition of resistance to therapeutic
agents through an increase in inflammatory mediators in
the cancer-cell microenvironment, or compromised drug
metabolism induced by such mediators associated with
CRP [21].
Tumor response to treatment is currently assessed by
imaging based on RECIST criteria [22]. However, al-
though marked central necrosis is often detected in le-
sions with a small size reduction after treatment with
TKIs, RECIST only considers one-dimensional lesional
size changes, suggesting that it may substantially un-
derestimate the actual tumor response. Several studies
recently reported novel criteria, which may improve
response assessment by evaluating changes in tumor
attenuation and morphology on contrast-enhanced com-
puted tomography scans in addition to size changes
[5,22-26]. The results of this study therefore need to
be interpreted carefully, because lesions in different organs
may exhibit distinct response patterns in imaging. More-
over, the current study did not demonstrate an association
between tumor response and patient survival, and it is
possible that percent change in tumor size might not cor-
relate directly with survival. Further studies are needed to
determine the influence of organ-specific response pat-
terns to TKI treatment on survival.Conclusions
The results suggest that tumor-size reduction depends
on initial tumor size and the organs involved, as well as
systemic reaction to the lung tumor, as indicated by CRP
levels. CCRCC patients with lung metastatic lesions <
20 mm in diameter and lower CRP levels may achieve
greater reductions in tumor size with sunitinib therapy
than those with extra-pulmonary lesions, lung lesions ≥
20 mm in diameter, and/or higher CRP levels.Abbreviations
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